Silence Therapeutics plc (SLN) Tops Q3 EPS

Silence Therapeutics plc (NASDAQ: SLN) reported Q3 EPS of (£0.07), £0.10 better than the analyst estimate of (£0.17). Revenue for the quarter came in at £2.8 million versus the consensus estimate of £2.94 million.

For earnings history and earnings-related data on Silence Therapeutics plc (SLN) click here.

You May Also Be Interested In

• The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
• Infinity Natural Resources, Inc. (INR) Tops Q2 EPS by 11c
• Team (TISI) Misses Q2 EPS by 215c ; Offers revenue guidance range